DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactStocks

ICICI PRUDENTIAL NIFTY PHARMA ETF Stock/Share price , NSE/BSE Forecast News and Live Quotes

Equitymaster 2 hrs ago·28 Oct 2026, 5:29 am

Stocks Equitymaster

ICICI Prudential Nifty Pharma ETF is an exchange-traded fund that tracks the performance of the Nifty Pharma Index. It allows investors to buy a basket of leading pharmaceutical companies in India through a single transaction, rather than selecting individual stocks.

For investors, this fund offers a convenient way to gain exposure to the pharma sector. It provides diversification across many companies, which can help reduce the risk associated with investing in a single stock. It is a passive investment option designed to mirror the index's returns.

Investors should watch for updates on the Nifty Pharma Index and the performance of the underlying pharmaceutical companies. Changes in government regulations, drug pricing policies, or global health trends can significantly impact the fund's value.